Trial Profile

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study and Open-Label Extension to Evaluate the Safety and Efficacy of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease (NEULARK)

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 02 Sep 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

17 Jun 2026 According to a Neuron23 media release, company announced that it has received a 2.5 million grant from The Michael J. Fox Foundation for Parkinsons Research (MJFF) to support expansion of the Phase 2 NEULARK clinical trial of NEU-411 into Israel.The funding supports activation of four clinical trial sites across Israel and patient screening efforts for people with early Parkinsons disease.
09 Jun 2026 Planned End Date changed from 1 Sep 2027 to 1 Jun 2028.
09 Jun 2026 Planned primary completion date changed from 1 Sep 2026 to 1 Dec 2027.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com